Tesamorelin
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
At a glance
- Best for
- Adults with HIV-associated lipodystrophy and excess visceral abdominal fat
- Typical dose
- 2 mg subcutaneously once daily
- Time to effect
- Weeks to months (visceral fat reduction measurable by ~3-6 months)
- Main caution
- Not approved for general weight loss or bodybuilding; raises IGF-1 and is contraindicated in active malignancy
What is it
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) given by daily subcutaneous injection. It stimulates the pituitary to release endogenous growth hormone, which in turn raises IGF-1 and reduces visceral fat. It is FDA-approved to reduce excess abdominal fat (lipodystrophy) in adults living with HIV.
Is it worth it for you?
Worth considering if…
- You are an adult with HIV and clinically significant excess visceral abdominal fat, prescribed and monitored by a clinician
- You can commit to daily subcutaneous injections and periodic IGF-1 monitoring
- Your visceral fat persists despite stable antiretroviral therapy
Probably skip if…
- You want a general weight-loss drug or cosmetic body recomposition (not its indication and benefit reverses on stopping)
- You have active or suspected malignancy
- You are pregnant, or have disruption of the hypothalamic-pituitary axis from tumor, surgery, radiation, or head trauma
Evidence at a glance
| Goal | Evidence | Effect | Best fit | Time |
|---|---|---|---|---|
| hiv-associated lipodystrophy (excess visceral abdominal fat) | Strong Evidence | Roughly 15-18% reduction in visceral adipose tissue versus placebo over 26 weeks | Adults with HIV and increased visceral abdominal fat on stable antiretroviral therapy | Weeks to months |
Evidence for 1 use
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
hiv-associated lipodystrophy (excess visceral abdominal fat)
Disease adjunctTwo phase-3 randomized, double-blind, placebo-controlled trials in adults with HIV and excess abdominal fat showed that 2 mg daily subcutaneous tesamorelin reduced CT-measured visceral adipose tissue by approximately 15-18% relative to placebo over 26 weeks, with continued benefit through 52 weeks in extension. Waist circumference and triglycerides also improved. Visceral fat re-accumulated after the drug was stopped, indicating ongoing therapy is needed to sustain the effect.
Bottom line: Daily tesamorelin meaningfully reduces excess visceral abdominal fat in HIV-associated lipodystrophy, but only while treatment continues.
How to take it
- Typical dose
- 2 mg (delivered as labeled, e.g. Egrifta SV 1 mg/1.5 mg reconstituted) subcutaneously once daily, prescribed by a clinician
- Timing
- Once daily; rotate injection sites on the abdomen
- With food
- Independent of food; administered subcutaneously, not orally
- How long to try
- Continued use is required to maintain effect; visceral fat re-accumulates after discontinuation, so the prescriber reassesses ongoing need
What to track
- Visceral adipose tissue / waist circumference
- Serum IGF-1 (to avoid sustained supraphysiologic levels)
- Fasting glucose and HbA1c (glucose tolerance can worsen)
- Injection-site reactions
Safety
Common side effects
Injection-site reactions (redness, itching, pain, bruising), Joint pain (arthralgia) and muscle pain, Peripheral edema and fluid retention, Carpal tunnel-type symptoms, Flushing or rash
Serious risks
- Elevated IGF-1, with theoretical concern for promoting neoplasia; contraindicated in active malignancy
- Worsening glucose tolerance / new or worsened diabetes
- Hypersensitivity and rare anaphylaxis
- Fluid retention that may exacerbate heart failure
Who should avoid it
- People with active or suspected malignancy
- People with disruption of the hypothalamic-pituitary axis (pituitary tumor, surgery, head radiation, or trauma)
- Pregnant individuals
- Anyone with hypersensitivity to tesamorelin or mannitol
Pregnancy & breastfeeding
Contraindicated in pregnancy — the benefit (fat reduction) provides no therapeutic value in pregnancy and IGF-1 elevation poses fetal risk.
Interactions
Tesamorelin can raise glucose and reduce insulin sensitivity, potentially requiring antidiabetic dose adjustment
Restoring GH/IGF-1 can alter CYP-mediated metabolism of co-administered drugs
GH affects cortisol conversion (11-beta-HSD), which may unmask cortisol insufficiency or require steroid dose changes
Choosing a product
Look for
- Only obtain via a licensed prescriber and pharmacy as FDA-approved Egrifta / Egrifta SV
- Supplied as a sterile lyophilized powder for reconstitution with proper diluent
- Dispensed with clinician instruction on subcutaneous injection technique and IGF-1 monitoring
Be skeptical of
- Grey-market or 'research-only' tesamorelin vials sold for bodybuilding or anti-aging
- Compounded or unverified peptide blends promising fat loss without a prescription
- Any source implying it is a general weight-loss supplement
References by claim
Track Tesamorelin with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.